Back to search

Belgium· BE-AMP-SAM202641-00

ReFacto AF 500 IU

A coagulation factor viii product containing moroctocog alfa, registered in Belgium by Pfizer Europe MA. The same ATC class is registered in 11 of our 19 countries.

ATC B02BD02

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedReFacto AF 500 IUATCB02BD02REGISTER NO.BE-AMP-SAM202641-00PACKS LISTED1CHECKEDSeptember 26, 2026

Where it is registered

Coagulation factor viii is registered in 11 of 19 countries.

Countries holding a registration under ATC B02BD02 (coagulation factor viii), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 7 of them publish a price we can compare per daily dose

Coagulation factor viii · ATC B02BD02

11 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Moroctocog Alfa
Manufacturer
Pfizer Europe MA
Country
Belgium (BE)
ATC code
B02BD02
ATC class
Coagulation factor VIII
Defined daily dose
1 TSD, E
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 1

  • be_apb
    1443183

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

4 interactions on record for coagulation factor viii.

Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Coagulation factor viii · interactions on record

4 records

  • 2 severe
  • 2 moderate

Most severe, free to view

  • CarfilzomibL01XG02severe
  • CarfilzomibL01XX45severe
  • PegvaliaseA16AB19moderate
  • EmicizumabB02BX06moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/9961129a-a570-4cb3-9369-7e2c1a2711e5
GET /v1/drugs/9961129a-a570-4cb3-9369-7e2c1a2711e5?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Powder and solvent for solution for injection",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "ReFacto AF 500 IU",
  "name_fr": "ReFacto AF 500 IU",
  "name_nl": "ReFacto AF 500 IU",
  "amp_code": "SAM202641-00",
  "strengths": [
    "500.0000"
  ],
  "pack_count": 1,
  "substances": [
    "Moroctocog Alfa",
    "Sodium Chloride",
    "Sucrose",
    "Polysorbate 80"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Coagulation Factor VIII",
  "authorisation_numbers": [
    "EU/1/99/103/002"
  ]
}

See everything about coagulation factor viii.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.